Please login to Zacks.com or register to post a comment.
They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.
Today, you can see them free.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| SCIENTIFIC L | SCIL | 8.00% |
| NATUS MEDICA | BABY | 6.11% |
| SUMMER INFAN | SUMR | 6.02% |
| RADIANT LOGI | RLGT | 5.32% |
| NEW ORIENTAL | EDU | 4.51% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
Shares of The Allstate Corporation ( ALL - Analyst Report ) hit a 52-week high of $41.25 on October 8, as the property & casualty insurer moves toward its third-quarter report next month. This Zacks #1 Rank's (Strong Buy) second quarter results included a 67% earnings surprise; its sixth straight quarter of outperformance.
Upbeat Earnings
Allstate Corporation is scheduled to report its third quarter results on November 1. The Zacks Consensus Estimate is at 98 cents on expected revenue of $7.3 billion.
On July 31, the company reported second-quarter 2012 operating earnings per share of 87 cents, rebounding from a loss of $1.24 per share in the year-ago quarter and topping the Zacks Consensus Estimate by 67.3%.
Solid numbers reflect lower catastrophe losses, which further led to reduced claims expenses, lower operating expenses and higher premiums. Expansions in emerging businesses and other personal lines along with higher investment income also benefited results. These were partially offset by lower realized capital gains and underperformance of Allstate Financial.
Allstates total net revenue edged up 2.4% year over year to $8.28 billion, substantially exceeding the Zacks Consensus Estimate of $7.3 billion.
Property-liability insurance claims and claims expenses significantly plunged 24.3% year over year to $4.81 billion.
Operating cash flow escalated 40.8% year over year to $1.77 million during the reported quarter.
The company bought back shares worth $275 million in the second quarter.
Earnings Momentum Heading North
For 2012, eleven of 24 estimates were revised upward in the last 30 days, pushing the Zacks Consensus Estimate higher by 4.6% to $4.34. This translates to a year-over-year increase of 228.6%.
The Zacks Consensus Estimate for 2013 rose 0.5% to $4.43 over the same time frame, representing a year-over-year increase of 2.1%.
Valuation Looks Attractive
Shares of Allstate Corporation currently trade at a forward P/E of 9.5x, a 25.8% discount to the peer group average of 12.8x. On a price-to-book basis, shares currently trade at 1.0x, a 10.3% discount to the peer group average of 1.2x. This looks attractive given that the trailing 12-month ROE is 10.5% versus 9.5% for the peer group average.
Market Performance & Technicals
Following the strong second quarter results, the companys shares moved above its 50-day moving average as well as the 200-day moving average. Shares have increased approximately 21% since Allstate Corporation released its second quarter results.
Volume is strong, averaging roughly 3.8 million daily. The year-to-date return for the stock came in at 50.3%, compared to the S&P 500s return of 15.7%.
Headquartered in Northbrook, Illinois, and founded in 1931, Allstate Corporation is a leading property-casualty insurer and the largest publicly-held personal lines carrier in the U.S. The company also provides a range of life insurance and investment products to its diverse customer base.
With a market capitalization of $19.98 billion, Allstate Corporation competes with Progressive Corp. (PGR), among others.
Want More of Our Best Recommendations?
Zacks' Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Then each week he hand-selects the most compelling trades and serves them up to you in a new program called Zacks Confidential.
Learn More>>
Read the full Analyst Report on ALL